DYN Q4 2016 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$791M+264.5% YoY

Gross Profit

$208M26.3% margin

Operating Income

$34M4.3% margin

Net Income

-$182M-23.0% margin

EPS (Diluted)

$-1.41

QoQ Revenue Growth

+228.2%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

-$40M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$13.1B

Total Liabilities

$11.0B

Stockholders' Equity

$2.0B

Cash & Equivalents

$1.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$791M	$217M	+264.5%
Gross Profit	$208M	-$317M	+165.6%
Operating Income	$34M	-$13M	+361.5%
Net Income	-$182M	-$134M	-35.8%